Press Release: Sanofi, Formation Bio and OpenAI announce
first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI announce
first-in-class AI collaboration
Paris, New York, N.Y.,
and San Francisco, CA, May 21, 2024.
Sanofi, Formation Bio and OpenAI are collaborating to build
AI-powered software to accelerate drug development and bring new
medicines to patients more efficiently. The three teams will bring
together data, software and tuned models to develop custom,
purpose-built solutions across the drug development lifecycle. This
represents a first collaboration of its kind within the pharma and
life sciences industries.
Sanofi will leverage this partnership to provide
access to proprietary data to develop AI models as it continues on
its path to becoming the first biopharma company powered by AI at
scale.
Paul Hudson CEO,
Sanofi“This unique collaboration is the next significant step in
our journey to becoming a pharmaceutical company substantially
powered by AI. Next generation, first-of-its kind AI model
customizations will be an important foundation in our efforts to
shape the future of drug development for pharma and for the many
patients waiting for innovative treatments.”
OpenAI, the world leader in AI technology, will
contribute access to cutting-edge AI capabilities, including the
ability to fine-tune models, deep AI expertise and dedicated
thought partnership and resources.
Brad LightcapCOO, OpenAI“There
is massive potential for AI to accelerate drug development. We are
excited to collaborate with Sanofi and Formation Bio to help
patients and their families by bringing new medicines to
market.”
Formation Bio, an AI and tech-driven drug
developer with its own pipeline of drug assets, will provide
extensive engineering resources, experience operating at the
intersection of pharma and AI, and its tech-driven development
platform to design, develop and deploy AI technologies across all
aspects of the pharma lifecycle.
Benjamine Liu Co-Founder
& CEO, Formation Bio “I firmly believe that by combining
our strengths, Sanofi, OpenAI and Formation Bio can reimagine drug
development in the pharma industry. By creating and implementing
customized AI agents and models designed for our industry,
companies like Sanofi and Formation Bio can begin to scale with
unprecedented productivity and transform the pace at which we bring
new medicines to patients.”
The potential positive impact of AI for patients
waiting for new treatments is tremendous and Sanofi, Formation Bio
and OpenAI plan to lead the way for drug developers.
About Formation BioFormation Bio is a
tech-driven and AI-native pharma differentiated by radically more
efficient drug development. Advancements in AI and drug discovery
are creating more candidate drugs than the industry can progress
because of the high cost and time of clinical trials. Recognizing
that this development bottleneck may ultimately limit the number of
new medicines that can reach patients, Formation Bio, founded in
2016 as TrialSpark Inc., has built technology platforms, processes,
and capabilities to accelerate all aspects of drug development and
clinical trials. Formation Bio partners, acquires, or in-licenses
drugs from pharma companies, research organizations, and biotechs
to develop programs past clinical proof of concept and beyond,
ultimately helping to bring new medicines to patients.
"Formation Bio" and "TrialSpark" are trademarks
of TrialSpark Inc.
About OpenAIOpenAI is an AI research and
deployment company. Its mission is to ensure that artificial
general intelligence benefits all of humanity.
This partnership was led by OpenAI’s COO and
approved by its independent Board of Directors.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across the world, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ:
SNY
Media RelationsEvan Berland |
+1 215 432 0234 | evan.berland@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.comTimothy
Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Investor RelationsThomas Kudsk
Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.comAlizé
Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Formation Bio Media
Relationspress@formation.bio
OpenAI Media RelationsSteve
Sharpe | + 1 650 224 2362 |
ssharpe@openai.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other
global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one
of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the
uncertainties discussed or identified in the public filings with
the SEC and the AMF made by Sanofi, including those listed under
“Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in Sanofi’s annual report on Form 20-F for the year
ended December 31, 2023. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Sanofi (BIT:1SAN)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Sanofi (BIT:1SAN)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024